-$0.09 Earnings Per Share Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter

Wall Street analysts expect that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will report earnings per share of ($0.09) for the current quarter, Zacks reports. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Pluristem Therapeutics also posted earnings of ($0.09) per share in the same quarter last year. The business is expected to issue its next earnings report on Monday, May 14th.

According to Zacks, analysts expect that Pluristem Therapeutics will report full year earnings of ($0.34) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.33). For the next year, analysts forecast that the business will report earnings of ($0.31) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Pluristem Therapeutics.

PSTI has been the topic of a number of analyst reports. Zacks Investment Research raised Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Thursday, March 15th. Maxim Group set a $3.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, HC Wainwright set a $4.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Pluristem Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.38.

In related news, Director Mark Germain sold 23,818 shares of the stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $1.50, for a total transaction of $35,727.00. Following the completion of the sale, the director now owns 559,817 shares in the company, valued at approximately $839,725.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.20% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC increased its stake in shares of Pluristem Therapeutics by 15.0% in the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 34,742 shares during the period. ARK Investment Management LLC boosted its position in shares of Pluristem Therapeutics by 363.5% in the 4th quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 228,149 shares during the last quarter. Finally, Meitav Dash Investments Ltd. bought a new position in shares of Pluristem Therapeutics in the 4th quarter worth $138,000. Institutional investors own 4.17% of the company’s stock.

PSTI stock traded down $0.04 during mid-day trading on Tuesday, hitting $1.20. The stock had a trading volume of 103,248 shares, compared to its average volume of 335,845. Pluristem Therapeutics has a 1-year low of $1.06 and a 1-year high of $2.12. The firm has a market cap of $133.04, a P/E ratio of -3.75 and a beta of 0.28.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3380024/0-09-earnings-per-share-expected-for-pluristem-therapeutics-inc-psti-this-quarter.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Investment Analysts’ Weekly Ratings Updates for Rhoen Klinikum
Investment Analysts’ Weekly Ratings Updates for Rhoen Klinikum
Verint Systems Sees Unusually Large Options Volume
Verint Systems Sees Unusually Large Options Volume
Kura Oncology Sees Unusually Large Options Volume
Kura Oncology Sees Unusually Large Options Volume
TopBuild  Hits New 52-Week High and Low at $84.52
TopBuild Hits New 52-Week High and Low at $84.52
Nu Skin Enterprises  Sets New 52-Week High and Low at $81.72
Nu Skin Enterprises Sets New 52-Week High and Low at $81.72
Jaguar Health  Shares Gap Down to $0.14
Jaguar Health Shares Gap Down to $0.14


© 2006-2018 Ticker Report. Google+.